Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases SAN DIEGO , Jan. 30, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases SAN DIEGO , Jan. 30, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
SAN DIEGO , Jan. 26, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces
View HTML
Toggle Summary Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
Study results to be presented at the Fifth AACR-IASLC International Joint Conference
View HTML
Toggle Summary Biocept Obtains Patent in Australia for its Molecular Biomarker Technology For the Detection of Cancer-Associated Mutations in Blood, Tissue, and Other Biological Sources
Expands intellectual property position to 22 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs)
View HTML
Toggle Summary Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota
Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota   SAN DIEGO (December 18, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock
SAN DIEGO , Dec. 6, 2017 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced that it has
View HTML
Toggle Summary First U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)
View HTML
Toggle Summary Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
Clinical validation of Biocept's novel PD-L1 test using multiple antibody clones has potential to improve detection, treatment selection, and patient monitoring with cancer immunotherapy
View HTML
Toggle Summary Biocept Reports Third Quarter 2017 Financial Results
-- Despite the impact from natural disasters and fewer sales days, revenues were up 6% and 111% in 3Q 2017 and year to date, respectively, versus the prior-year periods inclusive of the impact of conversion to accrual-based revenue recognition-- Distribution agreement signed with VWR to distribute Biocept's patented blood collection tube-- Co-Marketing agreement signed with Miraca Life Sciences-- Pathology Program initiative underway to expand adoption of Biocept's Target Selector™ platform to more community pathologists, oncologists and hematologists-- Newly launched liquid biopsy tests complete the complement of biomarker testing for breast cancer, metastatic melanoma and colorectal cancer under NCCN® Guidelines and bring the total number of commercially available liquid biopsy tests to 15-- Company to host conference call at 4:30 p.m. Eastern time today
View HTML